Jussi Paananen
Scientist, CTO, and Co-Founder in Bioinformatics, Genomics, and Digital Health
Helsinki, Finland
Summary
Jussi Paananen is a highly accomplished scientist and technology leader with a strong academic background, holding both an MSc in Computer Science/Software Engineering and a PhD in Molecular Medicine. He has contributed significantly to bioinformatics, genomics, and genetics research, evidenced by his over 80 peer-reviewed scientific publications, high citation metrics (h-index 41, i10-index 67), and affiliations with prestigious institutions like the University of Eastern Finland and the Broad Institute of MIT and Harvard. google+4
He possesses extensive leadership experience in technology, serving as Chief Technology Officer at Meru Health and Blueprint Genetics, and Executive Director of Advanced Diagnostics Technology at Quest Diagnostics. His roles have consistently involved directing and developing data science, AI, and software technology efforts, particularly in the context of clinical genetics and digital health. nitter+2
Jussi is a proven entrepreneur, having co-founded two biotech startups, including Genomi Solutions Ltd., where he also served as Chairman of the Board. He leverages his deep technical expertise to drive innovation and solve real-world problems in healthcare, emphasizing the purpose-driven impact of technology on patient care, such as automating the identification of disease-causing genetic variants. blueprintgenetics+1
His early interest in computers and programming, starting at age six, shaped his career trajectory towards roles where he combines his computational skills with biological and medical challenges. He champions strong team building and a work-life balance, fostering environments where professionals can thrive and contribute meaningfully. blueprintgenetics+1
Work
Education
Writing
Diagnostic yield of genetic testing in a multinational heterogeneous cohort of 2088 DCM patients
September 1, 2023Publication providing real-world genetic diagnostic testing data and insights for dilated cardiomyopathy patients.
An omics perspective on drug target discovery platforms
January 1, 2020Article providing an overview of different 'omics' approaches in drug target discovery.
Random forest-based imputation outperforms other methods for imputing LC-MS metabolomics data: a comparative study
January 1, 2019Comparative study on imputation methods for metabolomics data.
Indolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the Finnish Diabetes Prevention Study
January 1, 2017Scientific article on metabolites linked to type 2 diabetes risk.
Genetic background of extreme violent behavior
January 1, 2015Research investigating the genetic factors contributing to extreme violent behavior.
Effects of an isocaloric healthy Nordic diet on insulin sensitivity, lipid profile and inflammation markers in metabolic syndrome–a randomized study (SYSDIET)
January 1, 2013Research on dietary effects on metabolic syndrome markers.
Hyperglycemia and a common variant of GCKR are associated with the levels of eight amino acids in 9,369 Finnish men
January 1, 2012Study on genetic variants, hyperglycemia, and amino acid levels.